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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The inhibitory activity on intestinal α glucosidase by cyanidin 3 
rutinoside was examined in vitro and in vivo. The IC50 values of
cyanidin 3 rutinoside against intestinal maltase, and sucrase were
2,323 ± 14.8 and 250.2 ± 8.1 μM, respectively. The kinetic analysis
revealed that intestinal sucrase was inhibited by cyanidin 3 rutin 
oside in a mixed type manner. The synergistic inhibition also
found in combination of cyanidin 3 rutinoside with acarbose
against intestinal maltase and sucrase. The oral administration of
cyanidin 3 rutinoside (100 and 300 mg/kg) plus maltose or sucrose
to normal rats, postprandial plasma glucose was markedly sup 
pressed at 30–90 min after loading. Furthermore, the normal rats
treated with acarbose and cyanidin 3 rutinoside (30 mg/kg)
showed greater reduction of postprandial plasma glucose than
the group treated with acarbose alone. These results suggest that
cyanidin 3 rutinoside retards absorption of carbohydrates by inhi 
bition of α glucosidase which may be useful as a potential inhib 
itor for prevention and treatment of diabetes mellitus.
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Introduction Diabetes mellitus is one of the chronic diseases characterized
by hyperglycemia, dyslipidemia, and protein metabolism
which result from defects in both regulations of insulin secretion
and/or insulin action. The prevalence of diabetic patients world-
wide has dramatically increased due to modern lifestyle changes
and an increase of consumption of high-carbohydrate diets.(1)
Recently, it has been reported that postprandial hyperglycemia is
an important contributing factor for the development of diabetic
complications.(2) Current scientific evidence has demonstrated the
possibility of successfully preventing the onset of diabetes by
controlling postprandial hyperglycemia through the inhibition of
α-glucosidase and α-amylase activities, resulting in aggressive
delay of carbohydrate digestion to absorbable monosaccharide.(3)
The suppression of postprandial hyperglycemia subsequently delays
the progression of micro- and macro-vascular complications such
as microangiopathy, cardiovascular, and cerebrovascular diseases.(4)
Much effort has been extended in search of effective dietary
plants and fruits for the development of functional foods in order
to prevent and treat diabetes mellitus. They provide the bioactive
compounds with beneficial health effects, and their consumption
has been associated with reduced risk of developing diabetes
through inhibition of α-glucosidase and pancreatic α-amylase
activities.(5–7) Anthocyanins are versatile and plentiful flavonoid
pigments which are widely distributed in various human diets
through crops, vegetables, fruits, and red wine, suggesting the
benefit of daily intake of certain amounts of these compounds
from plant-based diets.(8) Interestingly, anthocyanins have been
intensively investigated for their mechanisms related to anti-
diabetic effect.(9) Numerous studies have documented that antho-
cyanins potentially inhibit intestinal α-glucosidases which have
renewed interest in the studies on delaying postprandial hyper-
glycemia.(10,11) Cyanidin-3-rutinoside, a natural anthocyanin, has
been found in litchi, black current, capulin and sweet cherry.(12)
Our previous study reveals that cyanidin-3-rutinoside exhibits an
inhibitory effect on yeast α-glucosidase in a non-competitive
manner.(12) However, no information is available about the inhibi-
tory effect of cyanidin-3-rutinoside related to intestinal α-glucosi-
dase, and studies regarding the combined effect of cyanidin-3-
rutinoside and acarbose have not been undertaken in vitro and in
vivo.
The current study was therefore carried out to investigate the
inhibitory effect of cyanidin-3-rutinoside against intestinal α-
glucosidase. In addition, the study was conducted to evaluate the
types of kinetic inhibition on intestinal α-glucosidase. Further-
more, the study was designed to investigate the combined effects
of cyanidin-3-rurinoside and acarbose on inhibition of intestinal
α-glucosidase. Finally, anti-hyperglycemic effect of cyanidin-3-
rutinoside was performed in normal rats by oral maltose and
sucrose tolerance test.
Materials and Methods
Materials. Rat intestinal acetone powder, 3,5-dinitrosalicylic
acid, glucose oxidase kits, quercetin-3-rutinoside were purchased
from Sigma Chemical Co. Ltd. (St. Louis, MO). Acarbose was
obtained from Bayer, Germany. All others chemicals used were
of analytical grade. Cyanidin-3-rutinoside chloride (C3R) was
synthesized from quercetin-3-rutinoside according to the previous
method.(13) After purification, the chemical structure of C3R (Fig. 1)
was confirmed by using 1H-nuclear magnetic resonance (NMR),
13C-NMR, Mass spectrometry data.
In vitro assay for the intestinal α glucosidase inhibitory
activity. α-Glucosidase inhibitory activity was followed ac-
cording to our previous report.(14) Briefly, rat intestinal acetone
powder (100 mg) was homogenized in 3 ml of 0.9% NaCl solu-
tion. After centrifugation (12,000 g × 30 min), the crude enzyme
(maltase = 0.68 units/mg protein, sucrase = 0.10 units/mg protein)
was incubated with 37 mM maltose (70 μL) or 56 mM sucrose
(40 μL) in 0.1 M phosphate buffer pH 6.9, and 20 μL of various
concentrations of C3R at 37°C for 30 min (maltase assay) and
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60 min (sucrase assay). The mixtures were suspended in boiling
water for 10 min to stop the reaction. The concentration of glucose
released from the reaction mixtures was determined by using
glucose oxidase kits.
Enzyme kinetics. In order to investigate the type of inhibi-
tion, the enzyme kinetic analysis was performed according to the
above reaction. Maintaining the quantity of sucrase constant at
0.10 units/mg protein and C3R (from 0.1 to 1.0 mM) was
measured in various concentrations of sucrose. The type of inhibi-
tion was calculated on the basis of Lineweaver–Burk by recipro-
cally plotted data (substrate concentration on horizontal axis and
velocity on vertical axis).
Combined effect of cyanidin 3 rutinoside and acarbose
on intestinal α glucosidase inhibitory activity. Acarbose was
combined with or without low concentration of C3R. The reaction
was performed according to the abovementioned assay. Results
are expressed as the percentage inhibition of the corresponding
control values.
Experimental animals. Male Wistar rats (180–200 g) were
obtained from the National Laboratory Animal Center, Mahidol
University, Salaya, Thailand. All animal experiments were
conducted according to the ethical guidelines outlined in the
Guide for Care and Use of Laboratory Animals. Animal facilities
and protocol were approved by the Laboratory Animal Care and
Use Committee at Faculty of Veterinary Science, Chulalongkorn
University, Thailand. Wistar rats were housed in individual stain-
less steel cages in a room maintained at 25 ± 1°C on a 12:12-h
light-dark cycle. They were fed standard laboratory chow with
water ad libitum and fasted overnight before the experiments.
Effect of cyanidin 3 rutinoside and its combination
with acarbose on plasma glucose concentration by the
oral maltose or sucrose tolerance test. Rats were randomly
assigned to 5 groups of 6 animals. Briefly, after overnight fasting,
group 1 was orally administered a vehicle (distilled water). Group
2, 3 and 4 received C3R (30, 100, 300 mg/kg). Group 5 received
acarbose (3 mg/kg). Thereafter, either maltose (3 g/kg) or sucrose
(3 g/kg) solution was administered as the second administration at
5 min after the first administration. Blood samples were collected
from the tail vein at 0 (before administration), 30, 60, 90, 120 and
180 min after substrate administration.
The combined effect of C3R and acarbose on plasma glucose
concentration was performed according to above-mentioned
method. Group 1 was orally administered a vehicle. Group 2
received C3R (30 mg/kg). Group 3 received acarbose (3 mg/kg).
The last group received C3R (30 mg/kg) plus acarbose (3 mg/kg).
Heparin-containing blood samples were immediately centrifuged
(2,000 × g), and the plasma was separated and frozen at −20°C
until analyzed for glucose concentration. Plasma glucose concen-
trations were determined by using the glucose oxidase kits. The
areas under the curve (AUC) of plasma glucose concentration
were calculated using a modification of the trapezoidal rule.
Statistical analysis. Data were expressed as means ± SEM
The IC50 values were calculated from plots of log concentration of
inhibitor concentration versus percentage inhibition curves by
using Sigma Plot 10.0. Statistical analysis was performed by
Student t test and one-way ANOVA. The least significant differ-
ence (LSD) test was used for mean comparisons and p<0.05 was
considered to be statistically significant.
Results
The IC50 values for the intestinal maltase and sucrase
activities. C3R inhibited the intestinal sucrase activity in a
concentration-dependent manner, whereas it slightly inhibited the
intestinal maltase activity. The IC50 values of C3R are summarized
in Table 1. The results showed that there was quite selective
inhibition on intestinal sucrase because the IC50 value for intestinal
maltase activity was much higher than that of sucrase activity.
However, C3R was much less potent than that of acarbose on the
intestinal maltase and sucrase inhibition.
The kinetic Inhibition of cyanidin 3 rutinoside on intestinal
sucrase. To further explore the inhibitory characteristics of
C3R, the kinetic assay was performed using Lineweaver-Burk
double reciprocal plots. The inhibitory mechanisms on the intes-
tinal sucrase by C3R are shown in Fig. 2. A Lineweaver-Burk plot
of C3R generated straight lines which had different intersections
on the X-axis in the second quadrant, indicating that type of
inhibition was of the mixed competitive and noncompetitive type.
The combined effect of cyanidin 3 rutinoside with
acarbose on the inhibition of α glucosidase in vitro. It was
of interest to establish whether C3R and acarbose might interact
synergistically or additively on the inhibition of intestinal α-
glucosidase activity. Accordingly, an assay was then performed on
the solutions containing acarbose alone or in mixture with a low
concentration of C3R (1 μM) which did not show the inhibitory
Fig. 1. The chemical structure of cyanidin 3 rutinoside (C3R).
Table 1. The IC50 values for intestinal α glucosidase (maltase and sucrase)
by cyanidin 3 rutinoside and acarbose.
Results are expressed as means ± SEM, n =3 .
Compounds
IC50 values (μM)
Maltase Sucrase
Cyanidin 3 rutinoside 2,323 ± 14.8 250.2 ± 8.1
Acarbose 2.7 ± 0.1 29.6 ± 3.5
Fig. 2. Lineweaver Burk plot for inhibitory activity of C3R on the intes 
tinal sucrase.doi: 10.3164/jcbn.10 116
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effect against intestinal maltase and sucrase activities. The
combined effect of acarbose with C3R on intestinal maltase and
sucrase inhibition are shown in Fig. 3. After the addition of C3R
to the assay system with various concentrations of acarbose, the
percentage intestinal maltase and sucrase inhibition increased
when compared with acarbose alone (Fig. 3). The results showed
that the percentage inhibition of mixtures was greater than the
sum of acarbose and C3R. These findings suggest that combina-
tion of C3R and acarbose produced the synergistic inhibition
against the intestinal maltase and sucrase.
Anti hyperglycemic effect of cyanidin 3 rutinoside on
plasma glucose concentration in vivo. A single oral admin-
istration study of C3R with intestinal maltase and sucrase inhibi-
tory activities was performed to clarify its anti-hyperglycemic
effect in normal rats by oral maltose, and sucrose tolerance test.
Fig. 4 shows the change in plasma glucose concentration during
the 180 min of experiment in maltose- and sucrose-loaded normal
rats. The results of the present study clearly show that a single
oral administration of C3R (100 and 300 mg/kg) significantly
suppressed a rise of plasma glucose concentration at 30, 60 and
90 min after maltose and sucrose administration (Fig. 4 A and B).
Thereafter, plasma glucose concentration returned to baseline
level at 120 min. The AUCs of rats treated with C3R (100 and
300 mg/kg) were significantly lower than those of untreated rats
(Fig. 5). However, C3R (30 mg/kg) did not exert any significant
effect on reduction of plasma glucose concentrations after oral
maltose, and sucrose loading.
To confirm the synergistic effect from in vitro, the normal rats
were fed C3R (30 mg/kg) combined with acarbose at a dose of
3 mg/kg (maltose and sucrose loading). There were no significant
differences in reduction of plasma glucose concentration between
C3R (30 mg/kg) and the control group. Given the combined
administration of acarbose and C3R (30 mg/kg) to the rats, it was
found that plasma glucose concentration was significantly lower
than that of acarbose alone at 30 min after administration of
maltose and sucrose (Table 2). In addition, the AUCs of rats
treated with acarbose plus C3R was significantly lower than that
of rats treated with acarbose alone.
Fig. 3. The percentage enzyme inhibition of acarbose and its combination with C3R (1 μM) on (A) intestinal maltase, and (B) intestinal sucrase. Re 
sults are expressed as mean ± SEM, n = 3. *p<0.001 compared to acarbose alone.
Fig. 4. The effects of C3R on plasma glucose concentration by oral (A) maltose and (B) sucrose tolerance test. Results are expressed as
means ± SEM, n =6 .  * p<0.05 compared with the control group. J. Clin. Biochem. Nutr. | July 2011 | vol. 49 | no. 1 | 39
©2011 JCBN
S. Adisakwattana et al.
Discussion
Cyanidin and its glycosides represent one of the major groups
of naturally occurring anthocyanins. Their mechanisms related
to anti-diabetic effect have been comprehensively identified
including the stimulatory insulin secretion,(15) and prevention of
insulin resistance.(16) C3R, one of anthocyanins, displays a wide
range of biological activities including antioxidant,(17) anti-
inflammatory,(18) and anti-cancer.(19) Previous studies reported that
C3R dose-dependently inhibited yeast α-glucosidase and it was a
more potent inhibitor than quercetin-3-rutinoside.(12) The current
study demonstrates that C3R has anti-hyperglycemic activity
through inhibition of intestinal α-glucosidase (maltase and sucrase)
which plays a major role in carbohydrate digestion. Inhibition of
intestinal sucrase by C3R was conspicuous, whereas intestinal
maltase was not so strongly inhibited. According to a previous
study, the presence of monosaccharide moiety at the 3-O-position
of cyanidin dramatically increased the potency of intestinal
sucrase inhibition.(20) When comparing the IC50 values of C3R
and cyanidin glycosides from the previous study, it seems that
C3R shows significant increase in potency of intestinal sucrase
inhibition over cyanidin and its glycosides, indicating that the
introduction of a dissacharide (rutinose) in the 3-O-position of
cyanidin may play a more important factor for increasing the
intestinal sucrase inhibitory activity than the presence of mono-
saccharide.
The effect of C3R on postprandial hyperglycemia was investi-
gated in normal rats by oral loading of maltose and sucrose. The
postprandial hyperglycemia was suppressed after co-administration
of C3R and substrates. The evidence confirms the findings from
the in vitro study, indicating that the effect of C3R on the delay of
dietary carbohydrate as well as disaccharides digestion is due to
its inhibition of α-glucosidase activity in the small intestine,
leading to suppression of postprandial hyperglycemia. Considering
the data obtained from this investigation, it suggests that inhibition
of α-glucosidase may be one of the possible mechanisms of C3R
on the reduction of plasma glucose. Moreover, we hypothesize
that C3R may also mediate its antihyperglycemic action via other
mechanisms such as stimulating insulin secretion and activating
glucose uptake in muscle and adipose tissues. However, it was
reported when black currant anthocyanins containing C3R (2.08
μmol/kg of body weight) was orally administered to human, C3R
could be detected in the plasma and the Cmax value was 46.3 ±
22.5 nmol/L, indicating that C3R was poorly absorbed to blood
circulation in humans.(21) Due to its low bioavailability, it is
possible that C3R does not appear to alter mechanisms for anti-
hyperglycemic effect through peripheral tissues such as stimu-
lating insulin secretion or activating glucose uptake. Hassimotto
et al.(22) proposed that one mechanism of uptake of C3R in the
small intestine probably involves sodium-dependent glucose trans-
Fig. 5. The effects of C3R on the total areas under the curve (AUC) of plasma glucose concentration by oral (A) maltose, and (B) sucrose tolerance
test. Results are expressed as means ± SEM, n = 6. *p<0.05 compared with the control group.
Table 2. The combined effect of C3R and acarbose on plasma glucose concentration in oral maltose and sucrose tolerance test
Data are expressed as mean ± SEM, n = 6 rats per group. *p<0.05 compared to control, #p<0.05 compared to acarbose.
Groups
Plasma glucose (mg/dl)
AUC (mg/dl.min)
0 min 30 min 60 min 90 min 120 min 180 min
Maltose loading
Control 75.8 ± 6.7 163.7 ± 8.8 148.7 ± 5.4 132.4 ± 4.6 117.0 ± 6.5 96.1 ± 10.0 23,400.1 ± 660.6
C3R (30 mg/kg) 86.6 ± 9.7 145.6 ± 9.0 152.3 ± 12.5 138.0 ± 10.3 114.2 ± 12.8 100.9 ± 7.1 22,899.1 ± 1934.6
Acarbose (3 mg/kg) 80.1 ± 5.1 139.4 ± 6.5* 120.8 ± 4.1* 124.4 ± 7.3 109.2 ± 4.6 96.1 ± 12.2 20,920.7 ± 500.5*
C3R(30 mg/kg) 
+ Acabose (3 mg/kg)
84.0 ± 7.3 118.6 ± 5.6*,# 119.1 ± 2.3* 108.6 ± 4.7*,# 107.2 ± 8.5 93.5 ± 7.6 17,859.1 ± 432.1*,#
Sucrose loading
Control 85.1 ± 2.9 134.4 ± 7.8 159.3 ± 6.0 156.5 ± 11.0 120.4 ± 11.6 107.8 ± 7.3 23,413.6 ± 915.2
C3R (30 mg/kg) 90.5 ± 3.2 125.1 ± 7.0 148.3 ± 7.3 125.6 ± 7.1* 116.0 ± 4.5 81.2 ± 10.3 21,459.2 ± 1,312.7
Acarbose (3 mg/kg) 85.6 ± 6.0 114.3 ± 3.5* 125.1 ± 6.5* 121.4 ± 9.0* 101.2 ± 8.3 99.2 ± 5.3 19,325.4 ± 373.6*
C3R (30 mg/kg) 
+ Acabose (3 mg/kg)
94.0 ± 5.7 99.8 ± 4.1*,# 109.7 ± 5.4*,# 105.3 ± 5.6*,# 95.3 ± 2.7 94.8 ± 6.8 17,786.3 ± 200.3*,#doi: 10.3164/jcbn.10 116
©2011 JCBN
40
porter 1 (SGLT1). Glucose and galactose are also transported across
the brush border membrane of the enterocytes by SGLT1. Form
this evidence, C3R may compete with glucose for binding site of
SGLT1 which may delay in glucose absorption, thus, eliciting a
rise in postprandial hyperglycemia. Another possible mechanism
of C3R may be involved in this pathway. To prove this hypothesis,
a further study is needed to pinpoint the inhibitory effect of C3R
on glucose transporter in small intestine.
Acarbose is an anti-diabetic drug used to treat type 2 diabetes
mellitus and, in some countries, pre-diabetes. A recent report
has shown that treatment of acarbose was associated with a 25%
reduction in the incidence of diabetes in subjects with impaired
glucose tolerance.(23) The administration of acarbose is associated
with a 20% reduction of the peak of postprandial hyperglycemia.
This effect may last for as much as 5 h, with an increase in the time
of glucose absorption that prevents glucotoxicity and the con-
sequent hyperinsulinaemia.(24) In general, interactions between
anthocyanins and pharmaceutical drugs have received minimal
study. It is possible that dietary intake of fruits and plants enriched
with C3R may interact with acarbose in diabetic patients who
use this drug to control plasma glucose level, such that it can have
a detrimental impact on treatment outcome. Therefore, it is
interesting and important to determine whether C3R produces a
synergistic or additive inhibition with acarbose against intestinal
α-glucosidases. Our present study reveals that combination of
acarbose with C3R significantly produces a synergistic effect,
suggesting that it would have significant clinical benefit of
combination therapy on controlling postprandial hyperglycemia
in diabetic patients. In addition, combined therapy with C3R may
reduce the dose of acarbose, the progressive increase in optimal
drug dosage, and costs associated with pharmaceutical disease
management.
Postprandial hyperglycemia is one of the earliest observable
abnormalities in diabetes mellitus. It has been established that
an increase in postprandial hyperglycemia could contribute to the
increase of hemoglobin glycosylation (HbA1c) by up to 25% in
inadequately controlled patients with type 2 diabetes.(25) The
decrease in HbA1c level could reduce the incidence of chronic
vascular complications in diabetic patients.(23) HbA1c is the
product of non-enzymatic reaction between glucose and amine
moiety of hemoglobin. This reaction, called glycosylation, involves
lots of other proteins, and it is the principal mechanism causing
glucotoxicity which generates free radicals which directly damage
proteins, lipids, and nucleic acids and contribute toward tissue
damage,(26) induces oxidizing vascular wall lipids and accelerates
atherogenesis in diabetic patients.(27) It has been reported that C3R
has antioxidant activity by being free radical scavengers.(28) This
suggests that intake of C3R would have another beneficial effect
in diabetic patients, since it prevents oxidative damage to cells by
its antioxidant activity and thus helps to slow down the develop-
ment of diabetic complications.
Considerable amounts of anthocyanins are ingested as con-
stituents of the human diet, 180–215 mg daily.(21) C3R is a natural
colorant found in red sweet cherry, blackcurrant and other fruits.
For example, red sweet cherry (Kordia) contains C3R, as a major
anthocyanin, yielding at 184 mg/100 g fresh weight.(18) Moreover,
it has been found that the abundant anthocyanins in mulberry
pigment are cyanidin 3-O-rutinoside (60%) and cyanidin 3-O-
glucoside (38%).(29) It is possible that consumption of C3R-
enriched fruits may suppress postprandial hyperglycaemia, helping
to the prevention of diabetic complications. Unfortunately, clinical
data on consumption of C3R-enriched fruits in diabetic patients
are limited. Further comprehensive pharmacological investiga-
tions of C3R-enriched fruits are required to evaluate its toxicity
and clinical efficacy for potential application in pre-diabetic or
diabetic patients.
The present investigation suggests that C3R is effective in the
lowering of postprandial hyperglycemia by mediating inhibition
of intestinal α-glucosidase. It also produces the synergistic inhibi-
tion when combined with acarbose. Further, C3R delays digestion
and absorption of dietary carbohydrates in the small intestine,
leading to suppression of an increased blood glucose level after a
meal. Consumption of C3R-enriched fruit and plants may help to
improve postprandial hyperglycemia which would offer a greater
benefit for the treatment and prevention of diabetic complications.
Furthermore, C3R can be developed as a nutraceutical food for
prevention and treatment of diabetes mellitus.
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